Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555943 | 0.87 | LIPG (0.56) | LPLLIPGCA1CA2TRPV1 | |
| SCHEMBL29952644 | 0.87 | LIPG (0.56) | LPLLIPGCA1CA2TRPV1 | |
| SCHEMBL31028375 | 0.86 | LPL (0.50) | LPLLIPGCNR1CNR2CA1 | |
| SCHEMBL1533780 | 0.86 | LPL (0.50) | LPLLIPGCNR1CNR2CA1 | |
| SCHEMBL7952837 | 0.84 | LPL (0.48) | LPLLIPGCA1CA2 | |
| SCHEMBL13885521 | 0.81 | CA1 (0.42) | CA1CA2 | |
| SCHEMBL2295096 | 0.80 | ENPP2 (0.44) | LPLLIPG | |
| SCHEMBL29730087 | 0.80 | ENPP2 (0.44) | LPLLIPG | |
| SCHEMBL8857763 | 0.80 | MAOB (0.38) | LPLLIPG | |
| SCHEMBL16188912 | 0.80 | LPL (0.44) | LPLLIPGCNR1CNR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117700385-A | Liquid crystal compound, composition and application thereof | 安徽宇贝新材料科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11639471-B2 | Compound, liquid crystal composition and high-frequency phase shifter | DIC CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| CN-110790641-B | Method for producing compound having oxydifluoromethylene skeleton | 大金工业株式会社 | 2023-02-28 | — | — | CN | disclosed |
| CN-107721811-B | Side-fluorine-containing biphenyl diluent for high-birefringence liquid crystal and synthetic method thereof | 陕西师范大学 | 2021-01-29 | — | — | CN | disclosed |
| CN-108531196-B | Liquid crystal compound containing dibenzofuran ring and preparation method and application thereof | 石家庄晶奥量新材料有限公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-106132915-B | Method for producing compound having oxydifluoromethylene skeleton | 大金工业株式会社 | 2020-03-31 | — | — | CN | disclosed |
| CN-110790641-A | Method for producing compound having oxydifluoromethylene skeleton | 大金工业株式会社 | 2020-02-14 | — | — | CN | disclosed |
| US-20190284475-A1 | LIQUID CRYSTAL COMPOUND AND A LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME | DAXIN MATERIALS CORP. (TW) | 2019-09-19 | — | — | US | disclosed |
| US-20180208849-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-2853523-B1 | Process for producing fluorine-containing biaryl compound | DAIKIN IND LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
| EP-1223209-B1 | Fluorinated fluorenes and use thereof in liquid crystal mixtures | CLARIANT INT LTD (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1223209-A1 | Fluorinated fluorenes and use thereof in liquid crystal mixtures | CLARIANT INTERNATIONAL LTD. (CH) | 2002-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | LPL 105/4885LIPG 711/4885CNR1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.